Celsion Corporation Reports First Quarter 2014 Financial Results And Provides Business Update

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAWRENCEVILLE, N.J., May 8, 2014 /PRNewswire/ -- Celsion Corporation /quotes/zigman/24125762/delayed/quotes/nls/clsn CLSN -4.20% , an oncology drug development company, today announced financial results for the first quarter ended March 31, 2014 and provided an update on its development program for ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III program for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news